WSJ Insight Model

Personalized Cancer Vaccine Supply Chain & Value Flow

Analyzing Moderna, Merck, Tempus AI & Personalis Individualized mRNA (mRNA-4157 / V940) Continuum

Clinical Trial Preset Scenarios:
End-to-End Cycle Time On Target
38.0 Days
Biopsy acquisition to initial vaccine infusion
Patient Attrition Risk Mod Risk
11.4%
Disease progression prior to dose availability
Total Regimen Pool Annualized
$525M
2,658 patient batches completed / yr
Diagnostics / AI Capture Picks & Shovels
$63.8M
Personalis + Tempus AI gross take

End-to-End Individualized Manufacturing Pipeline

Click any stage to focus cycle parameters. Real-time bottleneck detection flags critical path latency.

Active Platform: Personalis ImmunoID NeXT (Exome + Transcriptome)
STAGE 01COLLECTION
Tumor Biopsy & Blood Normal
Hospital & Clinical Site
4.0 Days
Logistics Lag:1.5 d
Sample Failure:4.5%
STAGE 02CRITICAL PATH
Ultra-Deep Genomic Sequencing
Personalis / Tempus AI
12.0 Days
Coverage Depth:1000x Exome
Assay Fee:$8,200
STAGE 03BIOINFORMATICS
AI Neoantigen & HLA Binding
Tempus AI / Moderna ML
3.0 Days
Epitopes Selected:34 Peptides
Compute Fee:$3,500
STAGE 04SYNTHESIS
Custom mRNA & LNP Formulation
Moderna GMP Facility
11.0 Days
Batch Scale:Single Patient
Batch Cost (COGS):$24,500
STAGE 05QC & DISTRIBUTION
Sterile Fill-Finish & Cold Chain
Moderna / Cryo-Logistics
5.0 Days
Release Sterility:14-d Accelerated
Cold Temp:-80°C Cryo
STAGE 06CLINICAL DELIVERY
Combination Infusion (+ Keytruda)
Merck / Oncology Site
3.0 Days
Anti-PD-1 Co-Admin:Pembrolizumab
Institutional Cut:$14,000